Clinical Trials Browser

mirdametinib × Dermatologic × Clear all

NCT06159166 2026-04-13

Mirda

Phase 1/2 Recruiting

CNSDermatologic

NF1

NCT07237100 2025-11-19

Mirdametinib in Patients With Advanced NF1-mutant Melanoma

Phase 2 Recruiting

CNSDermatologic

Melanoma, Neurofibromatoses

NCT00147550 2013-09-13

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

Phase 1/2 Terminated

BreastDermatologicGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Melanoma